ReviewMolecular cancer2026
Metabolic reprogramming in cancer: signaling pathways and therapeutic targets.
Review in Molecular cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Identification of a candidate PRODH allosteric inhibitor MBTP-15324: modulation of proline metabolite profiles and ECM-associated gene-expression changes in lung cancer cells.Journal of enzyme inhibition and medicinal chemistry · 2026Article
- Reprogramming immunometabolism: linking nutrient sensing, cell death, and therapeutic innovation.Immunologic research · 2026Review
- In Vitro Anti-Breast Cancer Effects ofInternational journal of molecular sciences · 2026Article
- Natural Products in Prostate Cancer: Crosstalk Among the Gut Microbiome, Androgen Receptor Signaling, and Epigenetic Regulation.International journal of molecular sciences · 2026Review
- Pharmacological activity, molecular mechanisms and therapeutic potential of erianin (Review).International journal of molecular medicine · 2026Review
- Review
- Cross-Cancer Detectability of ctDNA Biomarkers in Asian Populations: Implications for Pan-Cancer Detection.Cancer management and research · 2026Review
- Metabolic reprogramming networks in the gastric cancer tumor microenvironment: an integrated axis of nutrient competition, metabolic crosstalk, and immunosuppression.Frontiers in immunology · 2026Review
- Metabolic rewiring of the tumor microenvironment: therapeutic intervention of multi-pathway adaptations to impede cancer metastasis.Frontiers in molecular biosciences · 2026Review
- The TRIM-cancer paradox: BCG as a programmable vaccine platform and a mechanistic probe for rational immunotherapy design.Frontiers in immunology · 2026Review
- YBX1 as an adaptive RNA hub in cancer: linking state-dependent RNA regulation to tumor immunity, metabolic reprogramming, and therapy resistance.Frontiers in immunology · 2026Review
- Immune evasion driven by lipid metabolic reprogramming in endocrine-resistant HRFrontiers in immunology · 2026Review
- Screening of Metabolic Reprogramming-Related Diagnostic Biomarkers and Analysis of Immune Heterogeneity in Atopic Dermatitis Based on Multi-Cohort Validation.Clinical, cosmetic and investigational dermatology · 2026Article
- Hepatocellular Carcinoma Precursor Lesions: From Pathological Basis to Risk Stratification and Precision Intervention.Journal of hepatocellular carcinoma · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Metabolism is a general term for an ordered series of chemical reactions used to maintain life, and the maintenance of normal cellular activities cannot be separated from metabolism, which is the most basic feature of life. However, metabolic alterations have a dual role. In normal cells, metabolic dysregulation predisposes them to impaired energy acquisition, senescence and even apoptosis. In contrast, metabolic remodeling in tumor cells is advantageous for cancer cell growth and proliferation, driving tumor development and becoming a hallmark of cancer. The inherent heterogeneity and plasticity of many tumor cells themselves are often accompanied by unique alterations in energy metabolism that allow them to survive even in harsh environments where resources are scarce. Notably, tumor cells do not operate in isolation; their metabolic reprogramming is tightly intertwined with metabolic crosstalk and collaborative adaptations involving other components within the tumor microenvironment. Among these metabolic pathways, glycolysis remains the dominant metabolic pathway driving tumor growth and microenvironmental remodeling, even under oxygen-sufficient conditions. Additionally, amino acid, lipid, and polyamine metabolism have been identified as a metabolic regulators that support cancer cell growth, influencing the fate and function of other cells in the microenvironment through metabolite exchange. Targeting cancer metabolism and its interactions with the microenvironment has thus emerged as a promising strategy for treating various malignancies. This article systematically reviews the redistribution of metabolic activities during cancer progression, encompassing both cell-autonomous metabolic reprogramming and microenvironment-mediated metabolic synergy and adaptation. The aim is to provide novel insights and therapeutic strategies for the comprehensive treatment of cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.